ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Atara Biotherapeutics (ATRA)
Atara Biotherapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$8.30▼ -0.60%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Atara Biotherapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Atara Biotherapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Atara Biotherapeutics a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $7.21 and $9.26; in 9 out of 10, between $5.77 and $11.56. Estimated annual volatility is 65%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $95.2M
- 52-week high
- $19.15
- 52-week low
- $3.92
- Revenue (12 months)
- $6.2M
- Revenue growth (YoY)
- -6.3%
- Gross margin
- 82.4%
- Operating margin
- 29.7%
- Net margin
- 27.1%
- Return on equity
- -84.9%
- Free cash flow (12 months)
- $-12.5M
- Beta
- 0.11
What this means
ATLAS does not publish a fair value for ATRA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks ATRA has traded between $3.92 and $19.15. Today it is 56.7% below that high and 112% above its low.
On the business: revenue fell 6.3% year over year; net margin is 27.1%.
Its beta is 0.11: it tends to move less than the market.
About the company
Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy. Atara Biotherapeutics develops off-the-shelf cell-based therapies designed to address serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions.
Want to see everything about Atara Biotherapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Atara Biotherapeutics do?
Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy. Atara Biotherapeutics develops off-the-shelf cell-based therapies designed to address serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions.
What is the chance ATRA goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, ATRA ends the month between $7.21 and $9.26.
How big is Atara Biotherapeutics and what is its P/E ratio?
Atara Biotherapeutics's market capitalization is $95.2M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is ATRA?
ATLAS estimates annual volatility at 65%. In a typical month, half of the outcomes end between $7.21 and $9.26.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer